Assessment of tumor volumes (Supplementary Figures 3A, B) at the time of tissue harvest from this PD study and from a parallel in vivo study designed to evaluate anti-tumor efficacy and survival (Supplementary Figures 3C–F) revealed no significance between the XCR1Ab-IFNL53A and isoAb-IFNL53A fusion treatments, further suggesting multiple injections with the XCR1Ab-IFNL53A fusion was not maintaining a gain in cDC1 activation. Here, MPPE1 is linked to neoplasm.